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Abstract 
Biallelic somatic mutations of TCF1 coding for hepatocyte nuclear factor 1 (HNF1are found 
in 50% of the hepatocellular adenoma (HCA) cases usually associated to oral contraception. In 
rare cases, HNF1 germline mutations could also predispose to familial adenomatosis. In order 
to identify new genetic factors predisposing to HNF1 mutated HCA, we searched for mutations 
in genes involved in the estrogens metabolism. For 10 genes (CYP1A1, CYP1A2, CYP3A4, 
CYP3A5, COMT, UGT2B7, NQO1, GSTM1, GSTP1, and GSTT1), we did not find mutations nor 
differences in the allele distribution among 32 women presenting HNF1 mutated adenomas 
compared to 58 controls. In contrast, we identified a CYP1B1 germline heterozygous mutation in 
4 women among 32 presenting HNF1 mutated adenomas compared to none in 58 controls. We 
confirmed these results with the identification of 4 additional CYP1B1 mutations in a second 
series of 26 cases. No mutations were found in the control group extended to 98 individuals and 
only a known rare genetic variant in two controls was observed (P=0.0003). We performed an 
ethoxyresorufin O-deethylase (EROD) assay to evaluate the functional consequence of the 
CYP1B1 mutations. We found a reduced enzymatic activity of each CYP1B1 variant. In addition, 
an E229K CYP1B1 mutation was found in a woman with a germline HNF1 mutation in a 
familial adenomatosis context. In this large family, all the three patients with adenomatosis bear 
both HNF1 and CYP1B1 germline mutations. 
In conclusion, our data suggested that CYP1B1 germline inactivating mutations may increase the 
HCA incidence in women with HNF1 mutation. 
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Introduction 
Use of oral contraception is an important risk factor to develop hepatocellular adenoma 
(HCA), a rare benign liver tumor (1, 2). HCA usually occur as a single tumor, but multiple 
nodules can be observed and the presence of more than 10 nodules in the liver defines liver 
adenomatosis (3). Most HCA usually remain stable but can increase in size after withdrawal of 
oral contraceptives while they rarely regress (4, 5). The search for genetic alterations in HCA led 
to the identification of mutations in two genes: (a) biallelic inactivating mutations of the TCF1 
gene (chromosomal locus: 12q24.31) coding for the transcription factor Hepatocyte Nuclear 
Factor 1 (HNF1) (6), and at a lower frequency (b) activating mutations in the CTNNB1 gene 
coding for ß-catenin (7, 8). Recently, mutation screening of these two genes in 96 HCA allowed 
us to identify strong genotype-phenotype correlations and we proposed a new classification of 
HCA tumors (8). Biallelic mutations of the gene coding for HNF1are found in half of the HCA 
cases. They define a homogeneous group of tumors representing the most usual form of adenoma 
characterized by a marked steatosis (8). In 84% of these cases both HNF1 mutations in tumors 
are of somatic origin. In the remaining cases, one of the HNF1 mutations was germline and 
patients developed adenomatosis. Familial analyses performed in 4 independent germline 
adenomatosis showed that all 11 relatives who developed adenomatosis displayed a germline 
HNF1 mutation (9, 10). However, in these families, 16 individuals with a germline HNF1 
mutation did not develop any liver tumors. These observations suggested that germline HNF1 
mutations predisposed to liver adenomatosis with an incomplete penetrance and raised the 
possible existence of modifier genes.  
HCA with somatic HNF1 mutations appear mostly in women (97% of the cases) with 
77% of these using oral contraceptive (8). Among them, we identified 4 women who developed 
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multiple HNF1 mutated adenomas. These results raised the question of a potential role for a 
genetic predisposition to develop HNF1 mutated adenomas, possibly related to estrogens 
metabolism. 
In order to identify a genetic predisposition in women with somatic HNF1 mutated HCA 
or to find a gene modifying the penetrance of adenomatosis in germline HNF1 mutated patients, 
we search for alterations in candidate genes involved in estrogens metabolism. We screened a 
first group of 32 women with HNF1 mutated HCA for genetic variants by direct sequencing of 
11 genes (CYP1A1, CYP1A2, CYP1B1, CYP3A4, CYP3A5, COMT, UGT2B7, NQO1, GSTM1, 
GSTP1, and GSTT1). The genotypes were compared to those of 58 control women with a HNF1 
non-mutated benign hepatocellular tumor. We validated the identified variants in a second group 
of 26 women presenting a HNF1 mutated HCA and 40 control women. 
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Materials and Methods 
Patients 
 A group of 16 French university hospitals participated to this study. Criteria for patient 
inclusion were women with confirmed HNF1 mutated HCA and as control women with HNF1 
non mutated benign liver tumors surgically treated in the same hospitals and over the same 
period. A first group of patients was recruited between 1992 and 2003, and consisted in 32 
women with HNF1 mutated HCA and 58 women in the control group (25 HCA, 24 focal 
nodular hyperplasias and 9 telangiectatic focal nodular hyperplasias). A second group of patients 
was recruited from 2004 to 2006, and consisted in 26 women with HNF1 mutated HCA and 40 
women in the control group (23 adenomas, 11 focal nodular hyperplasias and 6 telangiectatic 
focal nodular hyperplasias). In the overall series, the mean age at diagnosis was 37 years old 
(ranging from 14 to 61) in HNF1 mutated HCA cases and 38 years old (ranging from 12 to 62) 
in controls. Among the patients with a HNF1 mutated tumor, 72% used an oral contraception 
(12 cases with missing data), in 6 cases one HNF1 mutation was germline (data was unavailable 
in 3 cases). In the control group, 89% of the women had an oral contraception (11 cases with 
missing data). Among the 156 women, 38 cases of HNF1 mutated adenomas and 31 cases of 
non-mutated tumors were previously described in Zucman-Rossi et al., and Bioulac-Sage et al., 
respectively (8, 11). All women but 4 were of European origin. 
A family extensively described in Reznik et al., was also completely genotyped in the 
present work (10). Briefly, the proband, a 17 years old female, presented hepatomegaly. She 
developed early-onset diabetes at the age of 32 years of age. Liver nodules were discovered and 
liver adenomatosis was confirmed by pathological diagnosis, which led to a familial screening for 
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diabetes and adenomatosis. Germline HNF1 mutations were found in 11 individuals and three 
of them were affected by adenomatosis defined by the presence of more than 10 lesions (Figure 
1). 
For all cases, a representative part of the HCA nodule, as well as of the non-tumor liver, 
was immediately frozen in liquid nitrogen and stored at –80°C until use for molecular studies. All 
diagnosis were reviewed by a panel of liver pathologists and mutations were searched in the 
HNF1 gene as previously described (8). In the present work gene variants were searched in 
non-tumor DNA and germline origin was validated by genotyping lymphocytic DNA. All 
patients were recruited in accordance with French law and institutional ethical guidelines. Ethical 
committee of the Saint-Louis hospital, Paris, France, approved the overall design of the study. 
Newly identified mutations were also tested in 92 unrelated women from the Centre d’Etude du 
Polymorphisme Humain (CEPH) families. The E229K CYP1B1 mutation was also tested in 125 
independent and Caucasian women from the Human Genome Diversity Project (HGDP) (12). 
 
Mutation screening 
 Eight genes were screened for mutations or polymorphisms by direct sequencing of PCR 
products: CYP1A1 (exons 2 to 7, 3’UTR), CYP1A2 (polymorphism IVS1+734G>A and exons 2 
to 7), CYP3A4 and CYP3A5 (exons 1 to 13), CYP1B1 (exons 1 to 3), COMT, NQO1, and 
UGT2B7 (exons 1 to 6). Sequencing was performed as previously described (6). All mutations 
were confirmed by DNA sequencing from 2 independent PCR amplifications. The screening for 
GSTM1, GSTP1 and GSTT1 variants was performed according to the protocol described by 
Cabelguenne et al., (13). Oligonucleotides sequences used for all PCR and programs are provided 
in the supplemental Table1. 
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 The screen of the E229K CYP1B1 mutation in the HGDP population was performed by a 
PCR-RFLP assay. Briefly, a 517 pb fragment was generated with the PCR primers (forward) 5’-
TGGCCAACGTCATGAGTGCC-3’ and (reverse) 5’ACTCAGCATATTCTGTCTCTAC-3’. 
The generated fragment contains two EarI sites, the E229K CYP1B1 mutation removes one of 
the EarI sites. 
 
Mutagenesis 
 CYP1B1*1 allele into the pDHFR mammalian expression vector (14) was a generous gift 
from T. Friedberg, University of Dundee, Dundee, UK. Wild type and mutated CYP1B1*1, 
CYP1B1*2 and CYP1B1*3 alleles were generated using the QuikChange® II XL Site-Directed 
Mutagenesis kit (Stratagene), according to the manufacturer’s conditions. Wild-type CYP1B1*1, 
CYP1B1*2 and CYP1B1*3 alleles are described in 
http://www.imm.ki.se/CYPalleles/cyp1b1.htm. Expression of CYP1B1 alleles in mammalian 
COS-1 cells was performed according to Bandiera’s conditions using lipofectAMINE reagent 
(Invitrogen) and the co-transfection of a pSV-ß-galactosidase vector (15). 
 
EROD assay on whole cells 
EROD assay was performed according to Bandiera’s conditions and as briefly described 
below. After transfection (48 h), cells were incubated with a 400 nM solution of 7-
ethoxyresorufin (Sigma-Aldrich) in PBS 1X at 37°C/5% CO2. The fluorescent product resorufin 
is released from EROD by CYP1B1. Fluorescence was measured in duplicate aliquots of 
supernatant at time = 0 min, 5 min and 10 min (excitation = 544 nm; emission = 590 nm). The 
amount of resorufin formed was calculated by comparison with a standard curve ranging from 30 
µM to 3.75 nM (16). 
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Quantification of Protein Expression 
After resorufin analysis, cells were lysed (lysis reagent as supplied for the ß-Gal Reporter 
Gene Assay chemiluminescent kit; Roche Molecular Biochemicals, Mannheim, Germany) and 
concentration protein was determined using a BCA protein assay (BCA Protein Assay Kit; 
Pierce). Lysates were subjected to immunoblot analysis employing a polyclonal anti-human 
CYP1B1 primary antibody (BD Gentest) according to the manufacturer’s instructions. EROD 
assay was normalized to the transfection efficiency determined with the ß-Gal Reporter Gene 
Assay chemiluminescent kit (Roche Molecular Biochemicals) according to the manufacturer’s 
instructions. 
 
Statistical analysis 
 Statistical analyses were performed using the GraphPad prism software version 4 
(GraphPad Software Inc., San Diego, CA). Frequencies of CYP1B1 mutations in patients with 
HNF1 mutations and in control populations were compared in contingency tables using a 
Fisher’s exact test. The different activities of the mutated and non-mutated alleles of CYP1B1 
were compared with a two-tailed, unpaired t test with 95% confidence intervals. 
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Results 
1- Genotype analysis  
We scanned for genetic variants in the CYP1A1, CYP1A2, CYP3A4, CYP3A5, COMT, NQO1, and 
UGT2B7 genes in the first series of patients including 32 women with HNF1 mutated tumors 
and 58 women presenting non HNF1 mutated benign liver tumor. Allele frequencies of all 
identified coding single nucleotide polymorphims (SNPs) in the two patient groups are provided 
in Table 1. We did not observe significant differences between the 2 groups and these frequencies 
were similar to those from in the SNP500 database. Moreover, we did not identify new variants 
in these genes when compared to available genetic databases. 
2- Identification of CYP1B1 mutations in patients with HNF1 mutated adenoma. 
Among the first series of 32 women with a HNF1 mutated adenoma, we identified an 
heterozygous CYP1B1 germline mutation in 4 individuals. No mutations or rare variant were 
observed in the 58 women presenting non HNF1 mutated benign liver tumor. Sequencing a 
second series of 26 cases with a HNF1 mutated HCA, we identified 4 additional women with a 
CYP1B1 germline mutation. None of the CYP1B1 identified mutations were found in SNP 
available databases (NIEHS, SNP500, dbSNP, Panther, Ensembl). No mutations were found in 
40 supplementary women presenting non HNF1 mutated benign liver tumor (Table 2). 
However, among this second control group, we identified two Caucasian individuals with a rare 
CYP1B1 heterozygous variant leading to an amino acid substitution at codon 81 (Y81N) never 
found in women presenting HNF1 mutated HCA (Table 2). The Y81N polymorphism is 
characterized as a rare variant in the SNP500 database with a 2% allelic frequency in Caucasian 
population. Taken together we found a significant association between CYP1B1 germline 
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mutation and the occurrence of HNF1 mutated adenoma (P = 0.0003, Fisher exact test). The 8 
identified mutated individuals corresponded to 4 different nucleotide mutations. An amino acid 
substitution at codon 229 (E229K) was observed in 5 cases. Two other amino acid substitutions 
(P52L and G329S) were found. The last mutation was a small deletion of 13 nucleotides leading 
to a frameshift (R355fs). We have tested a third control group of 92 independent women from 
CEPH collection for these mutations and none was found. Because the E229K CYP1B1 mutation 
was observed in five cases, we genotyped 125 additional Caucasian women from the HGDP 
collection. No E229K CYP1B1 mutation was observed in this population and we concluded that 
the E229K substitution was a mutation. 
Among the women with HNF1 mutated HCA, there were no significant differences in clinical 
characteristics (oral contraceptive use, age, number of nodules) when comparing CYP1B1 
mutated and non-mutated women. One of the E229K CYP1B1 mutations was found in a woman 
with a germline HNF1 mutation in a familial adenomatosis context. We genotyped 16 members 
of her family and identified the mutation in 8 relatives (Figure 1). We observed that the 3 cases 
with an adenomatosis (II-2, II-6, III-11) had both CYP1B1 and HNF1 mutations and only a 31 
years old man (III-6) without tumors presented both CYP1B1 and HNF1 mutations. 
Finally, no differences in the frequency of common CYP1B1 polymorphisms and alleles were 
observed between the 58 patients with HNF1 mutated HCA and the 98 control women 
presenting a non-mutated benign liver tumor (supplemental Table 2). 
3- Identified mutations decrease CYP1B1 enzymatic activity. 
The three different identified CYP1B1 mutations change evolutionary conserved amino acids in 
mammals (Figure 2) and the modified amino acids are all located either the hinge region or in 
some putative substrate recognition sites (SRSs) (17). We therefore tested for the functional 
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consequences of the different mutations using the 7-ethoxyresorufin O-deethylation (EROD) 
assay (15). The allelic context of the mutations P52L, E229K, G329S and R355fs were 
determined in the patients by cloning and sequencing CYP1B1 cDNA from non-tumor tissues of 
the corresponding patient. Interestingly, E229K were located in the same allele *2 in all 5 
mutated patients. Each mutation was introduced in its respective allelic context by site directed 
mutagenesis in a pDHFR plasmid. Wild type and mutated constructs were transfected in COS-1 
cells, which does not express CYP1B1 (15). CYP1B1 expression was assayed by immunoblotting 
48 h after transfection. A distinct and comparable signal was obtained by western-blot in cells 
transfected with all the CYP1B1 wild type and mutated alleles. CYP1B1*1-R355fs mutation was 
undetectable with the antibody since the variant encodes a protein in which the C-terminal that 
contains the epitope is modified by the frameshift mutation (Figure 3). We tested by quantitative 
RT-PCR the cells transfected with CYP1B1*1-R355fs and observed that CYP1B1 was expressed 
at a similar mRNA level when compared to wild type allele *1 (data not shown). The EROD 
activity of all normal and mutated alleles was determined after normalization to the transfection 
efficiency as previously described (15). Because CYP1B1*3 was the most frequently found allele 
in our tested populations (39% allelic frequency in all patients), we arbitrarily normalized our 
EROD assay results to the activity of this allele. We did not found any significant differences of 
activity between the 3 wild type alleles, CYP1B1*1, *2 and *3. In contrast, all mutated alleles 
exhibited a significant reduced activity when compared to their corresponding wild type allele 
(Figure 3).  
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Discussion 
Our study showed the identification of CYP1B1 germline heterozygous mutations in 14% 
of the women presenting a HNF1 mutated HCA. All identified CYP1B1 mutations led to a 
decreased enzymatic activity as tested using the EROD assay. We also identified a rare natural 
polymorphism (Y81N) in two women of the control group. Curiously, the Y81N CYP1B1 variant 
exhibited a reduced enzymatic activity as shown using the EROD test (supplemental figure 1). 
These results suggest that in vivo susceptibility to develop HNF1 mutated HCA is not only 
dependent on the in vitro EROD activity test and probably should be addressed with specific 
substrates. In fact, the EROD assay estimates the CYP1B1 activity by measuring the rate of 
cleaved resorufin, but it may reflect only partially the hydroxylation of endogenous substrates. 
We can hypothesize that, in vivo, the effects of the E229K and P52L CYP1B1 mutations would 
have a more important impact than the Y81N polymorphism towards endogenous substrates such 
as estrogens. We propose that CYP1B1 variants affecting specific domains such the hinge region 
or SRSs may act as potent genetic factors predisposing to the development of HNF1 mutated 
HCA in sporadic and familial cases. 
CYP1B1 mutations were first identified by Stoilov and collaborators in primary 
congenital glaucoma (PCG, OMIM#231300) (18). PCG is an autosomal recessive disorder that is 
associated with developmental defects of the anterior chamber (19) with an increase of the 
intraocular pressure leading to optic nerve damage and blindness. In the families presented by 
Stoilov et al., the CYP1B1 mutations were homozygous and co-segregated in the affected but 
normal members of the families. As shown in the present work using the EROD assay, the 
CYP1B1 mutations observed in PCG are expected to inactivate the cytochrome P450 activity 
(18). However, the precise mechanism by which CYP1B1 inactivation can lead to PCG remains 
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unknown. Two CYP1B1 mutations observed in women with HNF1 mutated HCA (E229K and 
R355fs) have already been reported in PCG. Another CYP1B1 mutation (P52L) observed in a 
woman with HNF1 HCA has recently been identified by Lopez-Garrido et al., in one individual 
of its control group (20). In contrast, the remaining mutation (G329S) observed in HCA had 
never been described before. 
CYP1B1 is also responsible for hormone metabolism and the hydroxylation of both 
endogenous and exogenous molecules that can lead to the formation of toxic metabolites (see for 
review Sissung TM, 2006) (21). The up-regulation of CYP1B1 is mediated by some sex 
hormones and their metabolites in addition to environmental carcinogens, such as polyaromatic 
hydrocarbons. Once up-regulated, CYP1B1 catalyzes the conversion of steroid hormones and 
exogenous substrates into hydroxylated metabolites. Depending on the hydroxylated molecule, 
this step of hydroxylation may increase the genotoxic and oxidative load on the cell and modulate 
cell signaling. This could further explain the role of CYP1B1 in neoplastic progression. CYP1B1 
is responsible for the hydroxylation of estradiol (E2) or estrone, and may form chemically 
reactive catechol estrogens (CE). Among the different CE, CYP1B1 catalyzes mainly the 
formation of 4-OH-estradiol (22) that may directly bind to DNA. The catechol estrogens (CE) are 
in majority inactivated by COMT which catalyses an O-methylation. If this inactivation is 
incomplete, the CE may be oxidized to reactive quinone capable of direct formation of DNA 
adducts. This step of oxidation also generates free radical formation. 
Several studies showed that CYP1B1 was implicated in the occurrence of tumors. First of 
all, Liehr et al. observed a significant and higher level of 4-hydroxylation of E2 in breast cancer 
microsomes compared with a very low level of 4-hydroxylation in normal breast tissue (23). 
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Moreover, immunohistochemical studies of CYP1B1 showed enhanced CYP1B1 in several types 
of human cancer including breast cancer (24, 25).  
Several polymorphisms within the CYP1B1 gene have also been implicated in different 
cancer risk. To date, the association between CYP1B1 polymorphisms and estrogens metabolism 
is unclear (see for review Sissung TM, 2006) (21). To our knowledge, this study is the first to 
associate a decreased activity of CYP1B1 with tumor occurrence in human. Since CYP1B1 is 
poorly expressed in the liver (24, 26, 27), we suspect that CYP1B1 reduced activity observed in 
our patients may be related to a peripheral effect of the perturbed estrogens metabolism. In this 
scenario, a decreased CYP1B1 activity in extrahepatic organs would lead to a saturation of 
hepatic cytochromes P450 and potentially disturb the estrogens metabolism in the liver. We 
propose a mechanism through an estrogen metabolites genotoxic effect leading to HNF1 
mutations to be at the origin of HCA. This hypothesis is consistent with the high rate of point 
mutations and more precisely of nucleotide tranversions observed in the spectrum of somatic 
HNF1 mutations identified in HCA (8).  
In conclusion, CYP1B1 germline inactivating mutations appears to predispose to the 
development of HNF1 mutated HCA in women. In addition, it seems to modify the penetrance 
of the liver adenomatosis phenotype in HNF1 germline mutated patients. However, the 
mechanism by which CYP1B1 inactivation predispose to the development of HNF1 mutated 
benign liver tumors remains to be elucidated. 
 
Jeannot et al 16 
Acknowledgements 
We warmly thank all the other participants to the GENTHEP (Groupe d’étude Génétique des 
Tumeurs Hépatiques) network: Charles Balabaud,
 
Michel Beaugrand, Jordi Bruix, Jacques 
Belghiti, Jean Frédéric Blanc, Pascal Bourlier, Paul Calès, Denis Castaing, Chen Liu, Marie 
Pierre Chenard-Neu, Daniel Cherqui, Laurence Chiche, Valérie Costes, Thong Dao, Daniel 
Dhumeaux, Amar Paul Dhillon, Jérôme Dumortier, Olivier Ernst, Monique Fabre, Dominique 
Franco, Frédéric Gauthier, Jean Gugenheim, Catherine Guettier, Emmanuel Jacquemin, Daniel 
Jaeck, Christophe Laurent, Brigitte Le bail, Sébastien Lepreux, Emmanuelle Leteurtre, Sophie 
Michalak, Anne de Muret, Frédéric Oberti, Valérie Paradis, Danielle Pariente, Christian 
Partensky, François Paye, François-René Pruvost, Alberto Quaglia, Pierre Rousselot, Anne 
Rullier, Antonio Sa Cunha, Marie Christine Saint-Paul, Jean Saric, Janick Selves, Elie Serge 
Zafrani, Dominique Wendum. We thank Cristel Thomas and Philippe Bois for critical reading of 
this manuscript. We thank Thomas Friedberg and Olivier Bernard, who provided protocols and 
cell lines; Lucille Mellottee, Sandra Rebouissou and Hung Bui for their technical help. We also 
thank all the clinicians, surgeons and pathologists of the Inserm GENTHEP network “Genetics of 
Hepatocellular Tumors”. 
Jeannot et al 17 
References 
1. Baum JK, Bookstein JJ, Holtz F, and Klein EW. Possible association between benign 
hepatomas and oral contraceptives. Lancet 1973;2:926-9. 
2. Edmondson HA, Henderson B, and Benton B. Liver-cell adenomas associated with use of 
oral contraceptives. N Engl J Med 1976;294:470-2. 
3. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver 
adenoma? Gastroenterology 1985;89:1132-8. 
4. Buhler H, Pirovino M, Akobiantz A, et al. Regression of liver cell adenoma. A follow-up 
study of three consecutive patients after discontinuation of oral contraceptive use. 
Gastroenterology 1982;82:775-82. 
5. Edmondson HA, Reynolds TB, Henderson B, and Benton B. Regression of liver cell 
adenomas associated with oral contraceptives. Ann Intern Med 1977;86:180-2. 
6. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic 
adenomas. Nat Genet 2002;32:312-5. 
7. Chen YW, Jeng YM, Yeh SH, and Chen PJ. P53 gene and Wnt signaling in benign 
neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular 
hyperplasia. Hepatology 2002;36:927-35. 
8. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in 
hepatocellular adenoma: new classification and relationship with HCC. Hepatology 
2006;43:515-24. 
9. Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with 
hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003;125:1470-5. 
Jeannot et al 18 
10. Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: 
cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset 
diabetes of the young (MODY)3 families. J Clin Endocrinol Metab 2004;89:1476-80. 
11. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular 
features defining so-called telangiectatic focal nodular hyperplasias of the liver. 
Gastroenterology 2005;128:1211-8. 
12. Cann HM, de Toma C, Cazes L, et al. A human genome diversity cell line panel. Science 
2002;296:261-2. 
13. Cabelguenne A, Loriot MA, Stucker I, et al. Glutathione-associated enzymes in head and 
neck squamous cell carcinoma and response to cisplatin-based neoadjuvant 
chemotherapy. Int J Cancer 2001;93:725-30. 
14. Ding S, Yao D, Deeni YY, et al. Human NADPH-P450 oxidoreductase modulates the 
level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -
independent pathways. Biochem J 2001;356:613-9. 
15. Bandiera S, Weidlich S, Harth V, et al. Proteasomal degradation of human CYP1B1: 
effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 
expression. Mol Pharmacol 2005;67:435-43. 
16. Li DN, Seidel A, Pritchard MP, Wolf CR, and Friedberg T. Polymorphisms in P450 
CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-
hydroxyestradiol. Pharmacogenetics 2000;10:343-53. 
17. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism 
with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33. 
18. Stoilov I, Akarsu AN, and Sarfarazi M. Identification of three different truncating 
mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital 
Jeannot et al 19 
glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. 
Hum Mol Genet 1997;6:641-7. 
19. Sarfarazi M, Akarsu AN, Hossain A, et al. Assignment of a locus (GLC3A) for primary 
congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity. 
Genomics 1995;30:171-7. 
20. Lopez-Garrido MP, Sanchez-Sanchez F, Lopez-Martinez F, et al. Heterozygous CYP1B1 
gene mutations in Spanish patients with primary open-angle glaucoma. Mol Vis 
2006;12:748-55. 
21. Sissung TM, Price DK, Sparreboom A, and Figg WD. Pharmacogenetics and regulation 
of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism 
and a novel target for therapeutic intervention. Mol Cancer Res 2006;4:135-50. 
22. Hayes CL, Spink DC, Spink BC, et al. 17 beta-estradiol hydroxylation catalyzed by 
human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-81. 
23. Liehr JG and Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary 
tumors. Proc Natl Acad Sci U S A 1996;93:3294-6. 
24. McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of 
cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for 
CYP1B1. J Histochem Cytochem 1999;47:1457-64. 
25. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome 
P450 CYP1B1. Cancer Res 1997;57:3026-31. 
26. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, and Kadlubar FF. In situ 
hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in 
human normal tissues. J Histochem Cytochem 2001;49:229-36. 
Jeannot et al 20 
27. Tang YM, Chen GF, Thompson PA, et al. Development of an antipeptide antibody that 
binds to the C-terminal region of human CYP1B1. Drug Metab Dispos 1999;27:274-80. 
28. van Schaik RH, van der Heiden IP, van den Anker JN, and Lindemans J. CYP3A5 variant 
allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668-71. 
29. Mammen JS, Pittman GS, Li Y, et al. Single amino acid mutations, but not common 
polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-
dihydrodiol. Carcinogenesis 2003;24:1247-55. 
30. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins 
inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol 
Chem 1992;267:83-90. 
 
Jeannot et al 21 
Table 1: Allele frequencies of all tested SNPs in the two groups of patients. 
Chromosomal 
loci 
Genotypes 
  Allelic frequencies   
Fisher 
exact 
test * 
Allelic 
frequencies 
  
32 women with a 
mutated HNF1a 
adenoma  
58 women with a 
non mutated benign 
tumor 
P value 
SNP500 
database 
22q11.2 COMT V158M Val 41% 49% 0.27 53% 
    Met 59% 51%   47% 
15q22 
CYP1A1 
T461N 
Thr 97% 99% 0.28 93% 
    Asn 3% 1%   7% 
15q22 
CYP1A1 
I462V 
Ile 98% 92% 0.09 89% 
  Val 2% 8%  11% 
15q22 CYP1A2 C 33% 34% 0.87 34% 
  IVS1-163 C>A A 67% 66%   66% 
2p21 CYP1B1 R48G Arg 77% 65% 0.12 75% 
  Gly 23% 35%  25% 
2p21 
CYP1B1 
A119S 
Ala 72% 65% 0.4 77% 
    Ser 28% 35%   23% 
2p21 
CYP1B1 
L432V 
Leu 56% 60% 0.63 55% 
  Val 44% 40%  45% 
2p21 
CYP1B1 
N453I 
Asn 75% 82% 0.33 81% 
    Ile 25% 18%   19% 
7q22.1 CYP3A5  G 91% ND ND 92% † 
 
IVS3-1387 
G>A 
A 9% ND  8% † 
1p13.3 GSTM1 null 44% 59% 0.19 47% †† 
    non-null 56% 41%   53% †† 
11q13 GSTP1 I105V Ile 67% 66% 1 69% 
  Val 33% 34%  31% 
22q11.2 GSTT1 null 41% 40% 1 29% 
    non-null 59% 60%   71% 
16q22.1 NQO1 P187S Pro 82% 84% 0.83 82% 
    Ser 18% 16%   18% 
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4q13 
UGT2B7 
H268Y 
His 47% 52% 0.63 ND 
    Tyr 53% 48%   ND 
* Comparison between the women with a mutated HNF1 adenoma and the women with a non 
mutated benign tumor. ND, Not Determined, † data from van Schaik et al. (28); †† data from 
Cabelguenne et al. (13). 
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Table 2: CYP1B1 germline mutations identified in tumors. 
  
CYP1B1 mutations   
Patients with 
mutated HNF1 
adenoma 
  Population control 
  
  
Nucleotide change Amino acid change   N = 58   N = 98 
  
  155 C>T P52L  1  0   
  684 G>A E229K  5  0   
  984 G>A G329S  1  0   
  1064_1076del R355fsX   1   0   
  Total  8  0   
  P value (Fisher exact test)    0.0003       
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Figure Legends 
 
Figure 1: Cosegregation of liver adenomatosis and CYP1B1 mutations. Patients are identified by 
generation numbers (roman numerals on the left) and individual number within each generation 
below the symbol. The second line under the symbols corresponds to the age of patients. Age in 
brackets corresponds to the age of death. The HNF1 and CYP1B1 genotypes of each tested 
patient are indicated on the third and fourth line, respectively (+/-, patients carrying either 
mutation; -/-, patients not carrying mutations). 
 
Figure 2: Protein diagram showing the locations of the mutations. The transmembrane segment, 
the hinge region, the meander region, the heme binding domain and the conserved helixes I, J, K 
and L were located according to Mammen et al. (29). The putative CYP1B1 SRSs, originally 
determined by Gotoh, were located according Watanabe et al. (17, 30). The alignments of amino 
acids of Human, Rat, Mouse, Opossum and Drosophila CYP1B1 gene were represented below 
each substitution.  
 
Figure 3: Effect of E229K, G329S, P52L and R355fs mutations on CYP1B1 catalytic activity. 
*1, *2 and *3 are the different non-mutated alleles of CYP1B1, defined by 3 polymorphisms. 
Each mutation was replaced in its haplotypic context, E229K and G329S in *2 allele, P52L in *3 
allele and R355fs in *1 allele (see Materials and Methods). The EROD activity is expressed as 
picomoles of resorufin per milligram of protein per minute and normalized to the total ß-
galactosidase activity representing transfection efficiency. Values are means +/- S.D. (n = 4 
replicates). EROD activity of the CYP1B1*3 allele was used as reference and fixed to 1. 
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Corresponding immunoblot analysis using an anti-CYP1B1 primary antibody are indicated by an 
arrow. 
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Jeannot Figure 2 
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